# A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

> **NCT03165721** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Paraganglioma
- Gastrointestinal Stromal Tumors
- Carcinoma, Renal Cell
- Renal Neoplasms
- Pheochromocytoma

## Interventions

- **DRUG:** SGI-110 (guadecitabine)

## Key facts

- **NCT ID:** NCT03165721
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-16
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study closed to enrollment due to low accrual.
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165721, "A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03165721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*